Executive Director, Global Medical Affairs, Lung

Summit Therapeutics Sub•Palo Alto, CA

1d•$231,000 - $289,000

About The Position

About Summit Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summits core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summits team is inspired to touch and help change lives through Summits clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than Chinas National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland. Overview of Role: The Executive Director, Medical Affairs, Lung is a key leader and a subject matter expert responsible for shaping and executing the medical affairs strategy in lung cancer. This role oversees the development and implementation of medical affairs plans for lung-related indications, including launch excellence for multiple indications, lifecycle management, and scientific engagement. The Executive Director will collaborate within the medical affairs department and cross-functionally with Clinical Development, Regulatory Affairs, Commercial, and Market Access teams to ensure effective, compliant, and impactful disseminations of data, education on disease and therapeutic information and interactions with healthcare professionals, key opinion leaders, and decision makers. Recent, hands-on experience in lung cancer, either in clinical practice or within pharmaceutical companies, is essential.

Requirements

Advanced scientific degree (MD, PharmD, PhD) required.
Minimum of 12+ years progressive Medical Affairs or related experience, with at least 5+ years in a leadership role.
Significant recent experience in lung cancer, either in clinical practice or within pharmaceutical/biotech companies, is required.
Proven track record of supporting product launches, building and optimizing medical affairs teams, and managing through leaders.
Excellent leadership, communication, and stakeholder management skills.
Strong analytical and strategic thinking abilities.
Demonstrates resilience, composure, and effective decision-making in a dynamic and challenging environment.
Ability to thrive in a matrixed, cross-functional environment.
Demonstrated ability to motivate, develop, and retain high-performing teams.
Willingness to travel up to 40% as needed.
Proficient user of standard MS Office suite (Word, Excel), experience using electronic document management systems, and document review tools.
Must be able to effectively multi-task and manage time-sensitive and highly confidential documents.
Work in a fast-paced, demanding, and collaborative environment.

Nice To Haves

Experience in a fast-paced, evolving environment preferred.

Responsibilities

Strategic Leadership Develop and lead the US medical affairs strategy for lung cancer, ensuring alignment with global medical, clinical, and commercialization objectives.
Oversee the design, execution, and reporting of medical activities supporting the launch and lifecycle management.
Foster a culture of high performance, collaboration, skills development, and scientific excellence across the medical affairs team.
Team Management Build and lead a high-performance, inclusive matrixed team grounded in scientific rigor and integrity.
Mentor, coach, and develop direct reports, ensuring effective coverage and execution of medical initiatives.
Scientific Engagement & Insight Generation Establish and maintain relationships with KOLs, HCPs, and other external stakeholders to support scientific exchange and gather actionable insights.
Ensure effective communication of scientific data and information to external stakeholders, representing Summit Therapeutics at scientific conferences, meetings, and other events.
Oversee the development and execution of pre-, peri-, and post-launch medical education programs, strategic publications, and data generation initiatives.
Cross-functional Collaboration Collaborate with Clinical Development, Regulatory, Commercial, and other internal stakeholders to ensure strategic integration and alignment of medical activities.
Compliance & Reporting Ensure all medical affairs activities comply with regulatory and company policies.
Monitor and report on activities, performance metrics, and outcomes to senior leadership.
Participate in the development and adherence to departmental SOPs and ensure all activities are legally compliant and conducted according to company standards.
All other duties as assigned